Back

The Role ACT Score in Mepolizumab Discontinuation

2023-09-29 allergy and immunology Title + abstract only
View on medRxiv
Show abstract

BackgroundMepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care. ObjectiveTo investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that there are characteristics tha...

Predicted journal destinations

1
PLOS ONE
1737 training papers
Top 10% 35.7%
2
Journal of Allergy and Clinical Immunology
15 training papers
#1 6.8%
3
Frontiers in Immunology
140 training papers
Top 3% 4.4%
4
European Respiratory Journal
44 training papers
Top 1% 3.2%
5
BMJ Open Respiratory Research
32 training papers
Top 1% 2.2%
6
Scientific Reports
701 training papers
Top 76% 2.2%
7
Journal of Medical Internet Research
81 training papers
Top 7% 2.2%
8
Thorax
29 training papers
Top 1% 2.2%
9
Vaccines
131 training papers
Top 4% 2.2%
10
Frontiers in Pharmacology
27 training papers
Top 1% 1.8%
11
Vaccine
140 training papers
Top 5% 1.8%
12
BMJ Open
553 training papers
Top 54% 1.5%
13
The Journal of Immunology
19 training papers
Top 0.7% 1.5%
14
Frontiers in Medicine
99 training papers
Top 17% 1.1%
15
International Journal of Environmental Research and Public Health
116 training papers
Top 24% 1.1%
16
Medicine
29 training papers
Top 4% 1.1%
17
Journal of Clinical Medicine
77 training papers
Top 17% 1.1%
18
Cureus
64 training papers
Top 15% 1.1%
19
Clinical Infectious Diseases
219 training papers
Top 22% 1.1%
20
ERJ Open Research
36 training papers
Top 3% 0.8%
21
Journal of Medical Virology
95 training papers
Top 13% 0.8%
22
Journal of Clinical Investigation
50 training papers
Top 7% 0.5%
23
Environmental Research
36 training papers
Top 5% 0.5%
24
Frontiers in Public Health
135 training papers
Top 38% 0.5%
25
Annals of the Rheumatic Diseases
23 training papers
Top 1% 0.5%
26
eLife
262 training papers
Top 63% 0.5%
27
Heliyon
57 training papers
Top 18% 0.5%
28
Science Immunology
15 training papers
Top 1% 0.5%
29
Cell Genomics
34 training papers
Top 7% 0.5%
30
Nature Communications
483 training papers
Top 64% 0.5%